https://corporate.meds.se//https://corporate.meds.se//om-meds/om-meds/https://corporate.meds.se//om-meds/kunderbjudande/https://corporate.meds.se//integritetspolicy/https://corporate.meds.se//media/pressmeddelanden/https://corporate.meds.se//media/pressmeddelanden/2026/meds-mangdubblar-logistikcenter-for-okad-kapacitet/https://corporate.meds.se//media/pressmeddelanden/2026/invitation-to-presentation-of-meds-2025-year-end-report-on-february-10-2026/https://corporate.meds.se//media/pressmeddelanden/2026/meds-year-end-report-2025-net-sales-exceeded-sek-1-billion-with-solid-growth-and-profitability/https://corporate.meds.se//media/pressmeddelanden/2026/meds-bokslutskommunike-2025-omsattning-over-miljarden-med-god-tillvaxt-och-lonsamhet/https://corporate.meds.se//media/pressmeddelanden/2025/stabilisation-notice-2025-10-17/https://corporate.meds.se//media/pressmeddelanden/2025/meds-interim-report-q3-2025-continued-strong-growth-with-profitability/https://corporate.meds.se//media/pressmeddelanden/2025/invitation-to-presentation-of-meds-q3-2025-interim-report-on-november-7-2025/https://corporate.meds.se//media/pressmeddelanden/2025/notice-of-stabilisation-measures-and-termination-of-stabilisation-period/https://corporate.meds.se//media/pressmeddelanden/2025/meddelande-om-stabiliseringsatgarder-och-avslutande-av-stabiliseringsperioden/https://corporate.meds.se//media/pressmeddelanden/2025/meds-avser-att-notera-sina-aktier-pa-nasdaq-first-north-premier-growth-market/https://corporate.meds.se//media/pressmeddelanden/2025/meds-delarsrapport-q3-2025-fortsatt-stark-tillvaxt-med-lonsamhet/https://corporate.meds.se//media/pressmeddelanden/2025/meds-intends-to-list-its-shares-on-nasdaq-first-north-premier-growth-market/https://corporate.meds.se//media/pressmeddelanden/2025/meddelande-om-stabiliseringsatgarder-2025-10-17/https://corporate.meds.se//media/pressmeddelanden/2025/stabilisation-notice/https://corporate.meds.se//media/pressmeddelanden/2025/meddelande-om-stabiliseringsatgarder/https://corporate.meds.se//media/pressmeddelanden/2025/meds-announces-the-outcome-of-the-offering-and-trading-on-nasdaq-first-north-premier-growth-market-commences-today/https://corporate.meds.se//media/pressmeddelanden/2025/meds-offentliggor-utfallet-av-erbjudandet-och-handeln-pa-nasdaq-first-north-premier-growth-market-inleds-idag/https://corporate.meds.se//media/pressmeddelanden/2025/meds-strengthens-the-board-with-two-new-members/https://corporate.meds.se//media/pressmeddelanden/2025/meds-starker-styrelsen-med-tva-nya-ledamoter/https://corporate.meds.se//media/pressmeddelanden/2025/meds-publishes-results-for-the-first-quarter-of-2025-strong-growth-with-record-high-profitability/https://corporate.meds.se//media/pressmeddelanden/2025/e-handeln-minskar-utslappen-ny-rapport-utmanar-myterna-kring-klimatsmart-konsumtion/https://corporate.meds.se//media/pressmeddelanden/2025/e-commerce-reduces-emissions-new-report-challenges-myths-about-climate-smart-consumption/https://corporate.meds.se//media/pressmeddelanden/2025/meds-publicerar-resultat-for-forsta-kvartalet-2025-stark-tillvaxt-med-rekordhog-lonsamhet/https://corporate.meds.se//media/prenumerera/https://corporate.meds.se//media/meds-i-media/https://corporate.meds.se//media/presskontakt/https://corporate.meds.se//media/pressbilder/https://corporate.meds.se//sok/https://corporate.meds.se//aktieinformation/aktiedata/https://corporate.meds.se//finansiell-information/meds-som-investering/https://corporate.meds.se//finansiell-information/rapporter-och-presentationer/https://corporate.meds.se//finansiell-information/rapporter-och-presentationer/meds-interim-report-q3-2025-continued-strong-growth-with-profitability/https://corporate.meds.se//finansiell-information/rapporter-och-presentationer/meds-delarsrapport-q3-2025-fortsatt-stark-tillvaxt-med-lonsamhet/https://corporate.meds.se//finansiell-information/rapporter-och-presentationer/meds-year-end-report-2025-net-sales-exceeded-sek-1-billion-with-solid-growth-and-profitability/https://corporate.meds.se//finansiell-information/rapporter-och-presentationer/meds-bokslutskommunike-2025-omsattning-over-miljarden-med-god-tillvaxt-och-lonsamhet/https://corporate.meds.se//finansiell-information/rapporter-och-presentationer/arsredovisning-2024/https://corporate.meds.se//finansiell-information/alternativa-nyckeltal/https://corporate.meds.se//finansiell-information/finansiell-kalender/https://corporate.meds.se//finansiell-information/utdelningspolicy/https://corporate.meds.se//finansiell-information/ir-kontakt/https://corporate.meds.se//finansiell-information/certified-adviser/https://corporate.meds.se//bolagsstyrning/bolagsstyrning/https://corporate.meds.se//bolagsstyrning/styrelse/https://corporate.meds.se//bolagsstyrning/ledning/https://corporate.meds.se//bolagsstyrning/revisor/https://corporate.meds.se//bolagsstyrning/bolagsordning/https://corporate.meds.se//bolagsstyrning/bolagsstamma/https://corporate.meds.se//bolagsstyrning/valberedning/